Article
The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses.
Frontiers in immunology - 1 Jan 2025
Scuoppo Claudio, Ramirez Rick, Leong Siok F, Koester Mark, Mattes Zachary F, Mendelson Karen, Diehl Julia, Abbate Franco, Gallagher Erin, Ghamsari Lila, Vainstein-Haras Abi, Merutka Gene, Kappel Barry J, Rotolo Jim A
Abstract excerpt
Immune-checkpoint inhibitors (ICIs) have shown unprecedented success in a subset of immunogenic tumors, however a host of patients with advanced solid tumors fail to respond well or at all to immunotherapy. Refractory tumors commonly display a tumor microenvironment (TME) rich in immunosuppressive macrophages (M2-like) that suppress adaptive immunity and promote tumor progression. The ability to reprogram...
Read the complete abstract on PubMedTopics
- Humans
- Animals
- CCAAT-Enhancer-Binding Protein-beta
- Mice
- Tumor Microenvironment
